SOURCE: Xtalks

Xtalks Webinars

April 25, 2017 07:00 ET

Outcomes-Based Agreements and Innovative Contracting for Biopharmaceuticals: Where Is The Market Moving?, New Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - April 25, 2017) - During a live broadcast on Wednesday, May 10, 2017, industry expert Janice Watch, Divisional Principal, Head of EU Pricing and Market Access from ICON Commercialisation and Outcomes will provide a deeper understanding of the changing contracting landscape and to learn ways to leverage new and innovative approaches to improve the commercial success of your biopharmaceutical products.

Key Insights

  • Learn why traditional contracting approaches may not be enough to address the needs of both payers and pharma manufacturers
  • Hear about current trends and anticipated innovations, including the use of outcomes-based agreements
  • Get insights on the key contracting issues you should be considering today to optimise the commercial success of your products


Launching a new drug often requires a compromise between the manufacturer and payer's objectives and priorities. While ensuring patient access to new drugs is an objective for both parties, payers also need to make certain that new therapies comply with budgetary constraints and that any associated risks of uncertainty are minimised. In this context, contracting represents mutually valuable agreements that address the needs of both the manufacturer and the payer.

Traditional contracting agreements have focused purely on price negotiations. These simple agreements such as, price discounting/rebates, caps and free goods, in themselves are not novel; however, their combination or inclusion in the context of a more complex agreement can be considered in the design of innovative contracting agreements.

When designing a contract, the aim is to find a cohesive solution that meets the needs of the payer while still achieving manufacturer objectives. Sometimes, "traditional" contracting is not sufficient to achieve this compromise, necessitating the adoption of more advanced, and sometimes complex, innovative contracting agreements.

Broadly speaking, innovative contracts can be classified as:

  • Outcomes-based agreements: linking the product's clinical outcomes with price and/or access
  • Financially-based agreements: employing novel financial mechanisms to manage risk and uncertainty
  • Value added services: leveraging technology and broader offerings to support product price and/or access, as a stand-alone agreement or more often in combination with an outcome- or financially-based agreement

Perceptions of innovative contracting and the use of outcomes-based agreements vary across markets. In Italy, where infrastructure for data collection is broadly available, payers are accustomed to outcomes-based contracts. In the US, outcomes-based contracting has been less common - though it is gaining traction and expected to play an increasing role in the future.

Join Janice Watch on Wednesday, May 10, 2017 at 11am EDT (4pm BST/UK). For more information or to register for this complimentary event, visit: Outcomes-Based Agreements and Innovative Contracting for Biopharmaceuticals: Where Is The Market Moving?

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit

For information about hosting a webinar visit

Image Available:

Contact Information